The pharmaceutical sector continues to rise, with innovation and overseas expansion emerging as key drivers.
Release time:
2023-03-02
This week, the pharmaceutical and biotechnology index rose by 1.88%, outperforming the CSI 300 index by 0.87 percentage points. Since the beginning of the year, the index has gained 3.93%. Sub-sectors such as medical R&D outsourcing, hospitals, and medical equipment have shown particularly strong performance.
This week, the pharmaceutical and biotechnology index rose by 1.88%, outperforming the CSI 300 index by 0.87 percentage points. Since the beginning of the year, the index has gained 3.93%. Sub-sectors such as pharmaceutical R&D outsourcing, hospitals, and medical devices have shown particularly strong performance. On the policy front, the "Implementation Plan for Supporting the Development of Innovative Drugs Across the Entire Value Chain" is steadily being put into practice. The success rate of negotiations with medical insurance providers has exceeded 90%, and the processes for pricing, payment, and hospital access of innovative drugs continue to be optimized. Meanwhile, the National Healthcare Security Administration is encouraging commercial health insurers to participate in the payment of innovative drugs, gradually refining a diversified payment system. Take BeiGene as an example: its core product, zanubrutinib, achieved global sales exceeding 8 billion yuan in the first three quarters of 2024, with more than 80% of sales coming from European and U.S. markets. Its A-share market capitalization has now surpassed that of Hengrui Medicine. Driven by the dual strategies of "innovation-driven development" and "expansion into overseas markets," domestically produced innovative drugs are steadily enhancing their global competitiveness and are poised to capture a larger share of the international market in the future.
Address: 6th Floor, Building C6, Jiangsu Life Science and Technology Innovation Park, Qixia District, Nanjing City
Official account